[evusheld] use for covid-19 under emergency use authorization (eua): administered tixagevimab to right ventrogluteal site.While administering this dose, noted small amount of fluid leaking from syringe and needle.Once injection complete- reviewed that needle was tightly secured- was not loose.Able to approx., that at least half of dose was received.Notified facility pharmacist.No further action needed.Pt tolerated both injections well and no reaction was noted in the 1 hour waiting period.Fda safety report id# (b)(4).
|